REG - Sareum Holdings PLC - Director Dealings

Sareum HoldingsAnnouncement

08/11/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231108:nRSH8299Sa&default-theme=true

RNS Number : 8299S  Sareum Holdings PLC  08 November 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Director Dealings

Cambridge, UK, 8 November 2023 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, announces the following share transactions
carried out by Directors.

As announced on 2 November 2023, Dr Tim Mitchell, Chief Executive Officer, and
Dr John Reader, Chief Scientific Officer, each exercised options over 95,040
ordinary shares of 1.25 pence each in the Company (the "Options Exercise"), at
an exercise price of 30 pence per ordinary share.

Of those shares received pursuant to the Options Exercise, Dr Mitchell and Dr
Reader have retained 23,040 and 44,614 ordinary shares, respectively,
following the sale of 72,000 and 50,426 ordinary shares, respectively, at a
price of 56.8 pence per ordinary share (the "Share Sales"). The Share Sales
were undertaken partly in order to compensate for the cost and tax liabilities
arising from the Options Exercise.

Following the Options Exercise and Share Sales, Dr Mitchell's and Dr Reader's
resultant interests in the Company will be as follows:

 Director/           Number of shares purchased pursuant to the Options Exercise  Number of shares sold pursuant to Sale Shares   Sale price   Resultant total number of ordinary shares held in the Company  Percentage of issued share capital

PDMR
 Tim Mitchell ((1))  95,040                                                       72,000                                         56.8p         1,032,561                                                      1.47%
 John Reader ((2))   95,040                                                       50,426                                         56.8p         1,077,111                                                      1.53%

(1) - Included within Tim Mitchell's total holding are 200,000 ordinary shares
held by his spouse.

(2) - Included withing John Reader's total holding are 66,666 ordinary shares
held by his spouse.

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

 

PDMR Notification Forms

 

The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Tim Mitchell
 2.  Reason for the Notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         SAREUM HOLDINGS PLC
 b)  LEI                                                          213800PKERN2DY8FFM72
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary shares of 1.25p each in the share capital of Sareum Holdings plc
     Identification code                                          ISIN for Ordinary Shares: GB00B02RFS12
 b)  Nature of the Transaction                                    Sale of ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  56.8p     72,000 sold
 d)  Aggregated information                                       Price(s)  Volume(s)

                                                            56.8p     72,000 sold
     -      Aggregated volume

     -      Price
 e)  Date of the transaction                                      7 November 2023
 f)  Place of the transaction                                     London Stock Exchange (AIM)

d)

Aggregated information

-      Aggregated volume

-      Price

 Price(s)  Volume(s)
 56.8p     72,000 sold

e)

Date of the transaction

7 November 2023

f)

Place of the transaction

London Stock Exchange (AIM)

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         John Reader
 2.  Reason for the Notification
 a)  Position/status                                              Chief Scientific Officer
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         SAREUM HOLDINGS PLC
 b)  LEI                                                          213800PKERN2DY8FFM72
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc
     Identification code                                          ISIN for Ordinary Shares: GB00B02RFS12
 b)  Nature of the Transaction                                    Sale of ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  56.8p     50,426 sold
 d)  Aggregated information                                       Price(s)  Volume(s)

                                                            56.8p     50,426 sold
     -      Aggregated volume

     -      Price
 e)  Date of the transaction                                      7 November 2023
 f)  Place of the transaction                                     London Stock Exchange (AIM)

d)

Aggregated information

-      Aggregated volume

-      Price

 Price(s)  Volume(s)
 56.8p     50,426 sold

e)

Date of the transaction

7 November 2023

f)

Place of the transaction

London Stock Exchange (AIM)

 

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBSBDBCUGDGXI